Pulmonary - Brinsupri Prior Authorization Policy
This Cigna prior authorization policy defines medical necessity criteria, prescriber requirements, approval durations, and non-covered uses for Brinsupri (brensocatib tablets) for treatment of non-cystic fibrosis bronchiectasis in patients aged 12 years and older.
Diagnostic requirement for initial therapy changed to 'history of bronchiectasis as diagnosed by chest computed tomography' and removal of prior five-year time limit.
Diagnostic requirement removed for patients currently receiving Brinsupri.
Exacerbation requirements updated to require that qualifying exacerbations resulted in prescription of an antibiotic agent for both pediatric and adult thresholds.
Requirement that respiratory symptoms are not driven primarily by COPD or asthma updated from a broader list of comorbid respiratory conditions.
Specialist prescriber requirement expanded to include infectious disease physicians in addition to pulmonologists.
Examples of beneficial clinical response for continuation therapy were updated to include reduced cough, reduced sputum production, or less shortness of breath.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.